| Not Yet Recruiting | A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 ) NCT07101328 | Eli Lilly and Company | Phase 1 |
| Not Yet Recruiting | A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) NCT07519772 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies NCT07476378 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | N/A |
| Recruiting | MOLyF : Bone Marrow and Follicular Lymphoma NCT06608147 | Rennes University Hospital | N/A |
| Withdrawn | PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL NCT06290622 | University of Alabama at Birmingham | Phase 1 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With NCT06425302 | Celgene | Phase 2 |
| Recruiting | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). NCT06213636 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies NCT06045910 | Cancer Research UK | Phase 1 / Phase 2 |
| Recruiting | Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries NCT05849857 | Oslo University Hospital | Phase 2 |
| Not Yet Recruiting | Long-term Ovarian Fertility in Patients Treated for Lymphoma. NCT05616325 | University Hospital, Lille | — |
| Active Not Recruiting | Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma NCT05410418 | Washington University School of Medicine | Phase 2 |
| Withdrawn | Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-deliver NCT05106192 | Case Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells NCT04911478 | Adicet Therapeutics | — |
| Terminated | Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study NCT04982471 | Celgene | — |
| Active Not Recruiting | A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhance NCT05228158 | Eisai Co., Ltd. | — |
| Completed | Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell NCT05784415 | AIDS Malignancy Consortium | — |
| Terminated | A Phase 1 Study of ADI-001 in B Cell Malignancies NCT04735471 | Adicet Therapeutics | Phase 1 |
| Active Not Recruiting | A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients Wi NCT03934567 | Xynomic Pharmaceuticals, Inc. | Phase 2 |
| Completed | A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysp NCT04036448 | Celgene | — |
| Unknown | Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma NCT03921879 | Oncotartis, Inc. | Phase 1 |
| Unknown | A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma NCT04370405 | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 2 |
| Completed | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma NCT03682796 | Triphase Research and Development III Corp. | Phase 1 |
| Completed | A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin L NCT03357627 | Calithera Biosciences, Inc | Phase 1 |
| Completed | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies NCT03310619 | Celgene | Phase 1 / Phase 2 |
| Completed | Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell NCT02257242 | Brown University | Phase 1 |
| Completed | A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogen NCT02809053 | Archigen Biotech Limited | Phase 3 |
| Completed | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine NCT02996773 | University of Arizona | Phase 1 |
| Withdrawn | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ib NCT02743546 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) NCT02669017 | ADC Therapeutics S.A. | Phase 1 |
| Completed | A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide NCT02631577 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Terminated | An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diff NCT02413489 | Janssen Research & Development, LLC | Phase 2 |
| Terminated | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies NCT02454270 | Janssen Research & Development, LLC | Phase 1 |
| Terminated | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors NCT02440685 | Asana BioSciences | Phase 1 / Phase 2 |
| Completed | A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or NCT02343536 | Celgene | Phase 1 |
| Completed | A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplant NCT02278796 | Insel Gruppe AG, University Hospital Bern | Phase 2 |
| Terminated | Safety Study of SEA-CD40 in Cancer Patients NCT02376699 | Seagen Inc. | Phase 1 |
| Completed | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) NCT02208037 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Ri NCT02162771 | Celltrion | Phase 3 |
| Active Not Recruiting | Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Pa NCT02390869 | Fondazione Italiana Linfomi - ETS | Phase 3 |
| Terminated | A Phase II Study of Doxycycline in Relapsed NHL NCT02086591 | University of Rochester | Phase 2 |
| Completed | Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low NCT01950273 | Boehringer Ingelheim | Phase 1 |
| Completed | Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon NCT03087929 | Sunnybrook Health Sciences Centre | — |
| Completed | Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim NCT03057418 | Biointegrator LLC | Phase 1 |
| Completed | A Safety Study of SGN-CD19A for B-Cell Lymphoma NCT01786135 | Seagen Inc. | Phase 1 |
| Terminated | An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma NCT01609036 | Hoffmann-La Roche | — |
| Completed | Study of Lymphoma in Asia NCT01584141 | National Cancer Institute (NCI) | — |
| Completed | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab NCT01307267 | Pfizer | Phase 1 |
| Withdrawn | Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas NCT01263418 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Completed | Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicula NCT01208896 | University Hospital, Bordeaux | Phase 2 |
| Completed | Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma NCT01234766 | Dartmouth-Hitchcock Medical Center | Phase 2 |
| Terminated | Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive NCT01077518 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Autologous Vaccine for Follicular Lymphoma NCT01022255 | Icon Genetics GmbH | Phase 1 |
| Completed | A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma NCT00930514 | Hoffmann-La Roche | Phase 1 |
| Completed | Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) NCT00864227 | Medical College of Wisconsin | Phase 2 |
| Completed | Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT NCT00849147 | Medical College of Wisconsin | Phase 2 |
| Completed | A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma NCT02472756 | Hoffmann-La Roche | — |
| Completed | Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL NCT00546793 | Gilead Sciences | Phase 1 / Phase 2 |
| Terminated | Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Fo NCT00562965 | Pfizer | Phase 3 |
| Completed | Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma NCT00915096 | Lymphoma Study Association | — |
| Completed | A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Pati NCT01164696 | Bayer | — |
| Completed | Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymph NCT00494780 | GlaxoSmithKline | Phase 2 |
| Completed | A Study of Enzastaurin in Participants With Follicular Lymphoma NCT00475644 | Eli Lilly and Company | Phase 2 |
| Completed | HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab NCT00394836 | GlaxoSmithKline | Phase 2 |
| Completed | Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab f NCT00427856 | Gemin X | Phase 2 |
| Terminated | Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma NCT00510887 | Duke University | Phase 2 |
| Terminated | Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lympho NCT00384111 | Spectrum Pharmaceuticals, Inc | Phase 3 |
| Terminated | Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a NCT00308087 | Genzyme, a Sanofi Company | Phase 2 |
| Terminated | An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participant NCT01902862 | Janssen-Cilag G.m.b.H | Phase 2 |
| Withdrawn | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Re NCT00319332 | GlaxoSmithKline | Phase 3 |
| Completed | A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma NCT00193492 | SCRI Development Innovations, LLC | Phase 2 |
| Completed | A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphom NCT02569996 | Hoffmann-La Roche | Phase 3 |
| Terminated | Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma NCT00060671 | CTI BioPharma | Phase 3 |
| Withdrawn | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma NCT00092274 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Completed | A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 1 NCT00315731 | GlaxoSmithKline | Phase 1 |
| Completed | Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study) NCT01250223 | Associazione Angela Serra per la ricerca sul cancro | — |
| Completed | A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma NCT00081809 | Agenus Inc. | Phase 2 |
| Unknown | FCM Versus R-FCM Followed by R-Maintenance or Observation Only NCT00317096 | Ludwig-Maximilians - University of Munich | Phase 3 |